arrow
P

Po-Ren Hsueh

National Taiwan University Hospital
H指数:106
被引数:5.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The implementation of the Infection Control Map—an integrated, visual online information system—enhanced infection control practices and reduced the incidence of multidrug-resistant organisms in a medical intensive care unit
2026-02-060
OAAI
Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration

采用美国临床和实验室标准研究所、欧洲抗菌药物敏感性试验委员会和食品药品监督管理局的标准,评估铜绿假单胞菌菌液微量稀释法和纸片扩散法对头孢地尼的敏感性解释一致性。

2025-12-011
PRE
Elevated Lactobacillus salivarius and genus Akkermansia in fecal samples of Taiwanese patients with parkinson’s disease and diabetes mellitus

台湾帕金森病和糖尿病患者的粪便样本中乳杆菌属Salivarius和属Akkermansia含量升高。

2025-11-260
OA
Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-2023

在2016-2023年抗菌药物检测领导力与监测(ATLAS)计划收集的数据中,柠檬酸杆菌属freundii、摩根氏菌属morganii、普罗威登斯菌属spp.和黏质沙雷氏菌marcescens临床分离株对头孢他啶-阿维巴坦的耐药性分布情况:覆盖五大洲。

2025-11-170
PRE
Optimizing antifungal dosing for invasive Cryptococcus infections: minimum inhibitory concentration distributions and pharmacokinetic/pharmacodynamic insights from 2010–2023 Antimicrobial Testing Leadership and Surveillance data

优化侵袭性新型隐球菌感染的抗真菌药物剂量:2010–2023年抗菌药物测试领导与监测数据中的最低抑菌浓度分布及药代动力学/药效学见解

2025-10-100
OAAI